Provider review
VevaRX Review: The Best Disclosure in This Sweep, on Pages That Lose Track of the Drug
VevaRX writes the compounding disclosure most of this market omits — unprompted, on every peptide page, in plain words. Its NAD+ education panel is the most careful copy we have read in this category: it describes what the molecule does in a cell rather than what it will do for you. Then the same NAD+ page quotes three different three-month prices spanning 180 dollars, and its banner announces a different peptide entirely.
Says the honest thing about compounding that most of this market won't, on pages that name the wrong drug and quote three prices for one plan.
Worth trusting if
- You want a seller that tells you compounded medicines are not FDA-approved without being asked
- You are buying sermorelin and want a page that promises you no outcome it cannot show
- You read the NAD+ education panel rather than the NAD+ headline
Be skeptical if
- You need the page price to be the price, because on three of four peptides it is not
- You want to know which pharmacy compounds your prescription, or who prescribes it, because neither is named
- You want a mailing address, because the refund clause asks you to write to one the site never gives
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens vevarx.com. A link is not a recommendation to take anything.
Provenance
What VevaRX actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin, three-month plan — Advertised at $399 on the card while the plan text, the billing text and the cart all say $367. Here the card is the outlier.
- NAD+, three-month plan — The card says $399, the plan text says $447, and the billing text says $267. The cart charges the card figure.
- Glutathione, three-month plan — The card and the cart both say $349 while the plan text and billing text say $267.
- PT-141 — $247 a month, or a three-month plan the page prices at $663 and the cart charges $598 — the one discrepancy here that runs in the buyer's favor.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 4 products reviewed here. The evidence belongs to the molecule, not to VevaRX.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from VevaRX’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Sermorelin, three-month planSermorelin · Compounded (503A)Claim matches the trials
“Sermorelin — Personalized wellness support with licensed provider oversight. Sermorelin is a provider-prescribed peptide therapy offered as part of an individualized treatment plan. Eligibility is determined by a licensed healthcare provider.”
Read on the VevaRX site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests energy, recovery, body composition or wellness in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
There is nothing here to correct, because there is no efficacy claim to check. "Personalized wellness support with licensed provider oversight" describes a service — a provider looks at your assessment and decides — and promises no outcome at all. That is genuinely rare: nineteen randomized sermorelin trials exist and none measured what this molecule is usually sold for, so a seller that declines to name an outcome is the only kind that cannot overreach. The page's problem is its price, not its claim.1
NAD+, three-month planNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+ — Support Energy, Focus, & Cellular Vitality.”
Read on the VevaRX site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
One page, two voices. The headline promises the buyer energy, focus and cellular vitality; the education panel a few hundred pixels below promises nothing of the kind, saying only that NAD+ "helps support the normal cellular processes involved in converting nutrients into usable energy" and that its role in aging "is being studied … though research is ongoing." The panel is accurate and admirably careful. The headline is the part in large type, and no completed randomized trial of injected NAD+ supports it.2
Glutathione, three-month planGlutathione · Compounded (503A)No trial supports this claim
“Glutathione — Support cellular detoxification, immune function, healthy aging, and reduce inflammation.”
Read on the VevaRX site, September 2026
No trial for this use
What the trials show for Glutathione
As of August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned seven records. Not one tests injected glutathione on its own for any of those outcomes. On ClinicalTrials.gov, 268 studies list glutathione as an intervention; restricting to injected routes returns three, in mantle-cell lymphoma, acute liver failure and pneumonia.
Four outcomes, and the last one is the strongest unhedged claim in this entire sweep. "Support" carries the first three; "reduce inflammation" drops the hedge and states a physiological effect flatly. No randomized trial of injected glutathione on its own has measured inflammation, or detoxification, or immune function, or aging. On a site that elsewhere writes with real care about what is and is not known, this sentence is the outlier.3
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“PT-141 — Provider-Guided Support for Sexual Desire.”
Read on the VevaRX site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
"Support for sexual desire" names exactly the outcome RECONNECT 1 and 2 measured across 1,437 participants, which is more than most sellers of this molecule manage. What it does not name is who those participants were: premenopausal women diagnosed with hypoactive sexual desire disorder. The page is open to any buyer, says nothing about sex or diagnosis, and never mentions that an approved version of this molecule exists.4
Dispensing chain
Who actually fills your prescription
Read the full account
Nobody in the chain is named. We searched all sixteen pages, visible text and underlying markup both, for every term a compounder or a prescriber is normally identified by — the two compounding categories, the phrase "compounded by", the prescriber identifier, "medical group", and both spellings of "doing business as" — and every single one returned nothing. The Terms offer one sentence: the product is "a compounded drug formulation prepared and shipped by an independent, state-licensed compounding pharmacy", which names a category rather than a company. No physician, medical director or advisory name appears anywhere; the About page describes "our dedicated remote team of professionals" and lists no people. What the site does state, and states well, is what a compounded preparation is not: every peptide page carries the line "Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing." One further oddity belongs in the record because it is published text rather than hidden markup: VevaRX's own Terms contain the sentence "All transactions on trimrx.com are conducted in United States Dollars (USD)", naming a domain that is not this company's. That tells a reader nothing about who owns what, and we draw no conclusion from it.
Read on the VevaRX site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published for any peptide. The site's LegitScript certification is genuine and its seal names vevarx.com, the live domain — but the word "LegitScript" appears in no text anywhere on the site, so a reader can only discover it by inspecting the image. Set against that, VevaRX's disclosure of what compounding means is the strongest in this batch and appears unprompted on every product page. The one place the site reaches for an evidence word, it substitutes a popularity claim: a homepage panel headed "Evidence-based GLP-1 care" explains itself as "custom-formulated compounded medications using ingredients commonly prescribed in medical practice." How commonly an ingredient is prescribed is not evidence about whether it works.
Read on the VevaRX site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
The FAQ enumerates 36 states: Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, Wisconsin and Wyoming. The Terms say twice that products are available across "the 50 U.S. states". Both statements are on the live site and they cannot both be right; the enumerated list is the more specific one, and it is fourteen states shorter.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel, and no people at all on the About page. The entity is VevaRx LLC. No physical address is published anywhere on the site, although the refund clause instructs customers to send written requests to "our physical mailing address", and the governing-law clause is circular, naming "the state in which VevaRx operates" without ever saying which state that is.
Read on the VevaRX site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Every peptide page carries, unprompted, the clearest compounding disclosure in this batch: compounded medications are not FDA-approved and the FDA does not verify their safety, effectiveness or quality.
- Its NAD+ education panel is the most careful writing we found in this category — it describes the molecule's role in a cell rather than promising the buyer an outcome, and says the aging research is ongoing.
- Its sermorelin page makes no efficacy claim at all, which on this molecule is the only honest position available.
Show 5 more
- Prices are visible before any intake, account or questionnaire.
- Its PT-141 page names the outcome the phase 3 trials actually measured.
- Its LegitScript certification is real and points at the live domain.
- The PT-141 cart charges less than the page advertises, not more.
- No FDA warning letter against VevaRx LLC.
- The NAD+ page quotes three different three-month prices — on the card, in the plan text and in the billing text — spanning 180 dollars.
- Sermorelin and glutathione each show two prices, and on sermorelin the advertised card figure is the wrong one.
- The NAD+ page's banner announces sermorelin.
Show 8 more
- The sermorelin, NAD+ and glutathione pages each carry a disclaimer about compounded tirzepatide.
- A complete tirzepatide sales block is appended to all three of those peptide pages.
- The glutathione claim drops its hedge on the last item and states flatly that the product will reduce inflammation.
- "Evidence-based" is glossed on the homepage as ingredients "commonly prescribed in medical practice", which is popularity, not evidence.
- No pharmacy, no clinician and no physical address is published anywhere — while the refund clause tells customers to write to a mailing address.
- The Terms claim 50-state availability twice; the FAQ enumerates 36.
- "Add an image in the theme editor" renders as visible text on the sermorelin and glutathione pages.
- The contact page answers "How do I take Semaglutide or Tirzepatide?" with instructions to mix a scoop of a powdered supplement into cold water.
Verdict
The bottom line
Read the price in the cart, not on the page — on three of the four peptides they differ, and only on PT-141 does the difference favor you. Then give VevaRX the credit it has earned: it states plainly that compounded medicines are not FDA-approved, its sermorelin page promises nothing it cannot show, and its NAD+ education panel is more careful than anything else we read in this sweep. The trouble is that the same page's headline promises energy, focus and vitality, and its banner is announcing a different peptide.
Opens vevarx.com. A link is not a recommendation to take anything.
The part VevaRX gets right
Most sellers in this market either bury the word "compounded" or never write it. VevaRX puts this at the foot of every peptide page, unprompted:
"Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing."
And its NAD+ education panel is the most careful copy we have read in this category. Watch what it is careful about:
"NAD+ helps support the normal cellular processes involved in converting nutrients into usable energy."
"NAD+ is being studied for its role in age-related cellular processes, though research is ongoing."
Those are claims about what a molecule does inside a cell. They are not claims about what will happen to you. The distinction is the whole ballgame in this category, and almost nobody draws it.
The panel then closes with a line saying the information "is not intended to diagnose, treat, cure, or prevent any disease."
Full analysis — 5 more sectionsAnd then the headline on the same page · Three prices for one plan · The pages lose track of the drug · One claim that drops the hedge · What is not published
And then the headline on the same page
NAD+ — Support Energy, Focus, & Cellular Vitality
That is a promise to the buyer, in the largest type on the page, sitting a few hundred pixels above a panel that pointedly declines to make it. No completed randomized trial of injected NAD+ in humans supports it. 2
One page, two voices, and the loud one is the one that isn't supported.
Three prices for one plan
The NAD+ page, read top to bottom on the same visit:
| Where on the page | Three-month price | |---|---| | The plan card | $399 | | "Important Plan Information" | $447 | | The billing detail | $267 | | What the cart charges | $399 |
A 180-dollar spread on a single product page. The card happens to be right.
On sermorelin it is the card that is wrong — $399 advertised, $367 in the plan text, the billing text and the cart. On glutathione the card is right again at $349 while the prose says $267. And PT-141 is advertised at $663 for three months and charged at $598.
Three of the four peptide pages disagree with their own checkout. Read the cart.
The pages lose track of the drug
The NAD+ page's announcement banner, at the very top:
"Sermorelin is a provider-prescribed peptide therapy offered as part of an individualized treatment plan."
The sermorelin, NAD+ and glutathione pages each carry this disclaimer:
"Compounded Tirzepatide is not FDA-approved and may vary in appearance from product images shown."
And below the fold, all three of those peptide pages carry a complete tirzepatide sales block — its own heading, its own plans, its own prices.
That last one is worth flagging for a specific reason: reading only the top of those pages, the tirzepatide block's $167 monthly and $467 quarterly figures look like a fourth conflicting peptide price. They aren't. $467 ÷ 3 = $155.67, exactly as printed. It is a wrong-product block, not a wrong price — and the difference matters if you are trying to work out what you will pay.
One claim that drops the hedge
VevaRX's glutathione tagline:
"Support cellular detoxification, immune function, healthy aging, and reduce inflammation."
Three hedged items and then a flat physiological assertion. Searched to August 2026, seven randomized records exist for injected glutathione across skin, detoxification, fatigue and energy outcomes, and not one tests injected glutathione on its own. 3 On a site that elsewhere writes so carefully about the limits of what is known, this is the sentence that doesn't belong.
What is not published
No pharmacy. No clinician. No address.
We searched all sixteen pages, visible text and markup both, for every term a compounder or prescriber is normally identified by. All of them returned nothing. The Terms say the product comes from "an independent, state-licensed compounding pharmacy" — a category, not a company.
The address gap has a practical edge: VevaRX's refund clause tells customers to send written requests to "our physical mailing address", and no page gives one.
Questions
Frequently asked questions
Which price will I actually be charged?
The cart's. On three of the four peptides the page and the checkout disagree: sermorelin advertises $399 and charges $367; NAD+ shows $399, $447 and $267 in three places and charges $399; glutathione shows $349 and $267 and charges $349; PT-141 advertises $663 for three months and charges $598. Take the product to checkout before deciding.
Why does the NAD+ page mention sermorelin?
Its announcement banner carries sermorelin's text. The sermorelin, glutathione and PT-141 banners each name their own product correctly, so this is one page's error rather than a site-wide pattern. Those three pages have a different version of the same problem: a disclaimer about compounded tirzepatide, and a full tirzepatide sales block below the fold.
Is the NAD+ claim supported?
The headline is not; the education panel below it does not make one. "Support Energy, Focus, & Cellular Vitality" has no completed randomized trial of injected NAD+ behind it. The panel underneath says only that NAD+ helps support normal cellular processes and that the aging research is ongoing — which is accurate, and is a claim about the molecule rather than about you.
Does VevaRX say its medicines are FDA-approved?
No — it says the opposite, on every peptide page, without being asked. "Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing." That is the clearest disclosure of any seller in this batch and it deserves saying plainly.
Which pharmacy compounds these, and who prescribes them?
Neither is named. We searched all sixteen pages, visible text and markup, for every term a compounder or prescriber is normally identified by, and every one returned nothing. The About page describes "our dedicated remote team of professionals" and names no people. No physical address is published either, although the refund clause asks customers to write to one.
Is it available in my state?
The site gives two answers. Its Terms say twice that products are available across the 50 U.S. states; its FAQ enumerates 36. The enumerated list is the more specific of the two and is fourteen states shorter, so check it before ordering.
Does VevaRX hold an FDA warning letter?
No FDA warning letter. We searched FDA's warning-letter database for "VevaRx", "VevaRX", "Veva Rx" and "VevaRx LLC", and all came back empty. We also searched "TrimRx" and "Trim Rx", because VevaRX's own Terms contain a sentence referring to trimrx.com, and those came back empty too. That sentence tells a reader nothing about who owns what, and we draw no conclusion from it.
Glossary
Key terms
Show definitions
- Compounded medication
- A preparation made by a pharmacy for a specific prescription rather than manufactured under an FDA approval. It has not been reviewed by FDA for safety, effectiveness or quality — which is exactly what VevaRX's own disclosure says.
- Evidence-based
- A claim that a practice is supported by studies of whether it works. It is not the same as a claim that an ingredient is widely prescribed, which is a fact about prescribing habits.
Compare
Others selling what VevaRX sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
- Belle HealthAlso sells Sermorelin · 3 of 3 claims match the trials
- Pallas HealthAlso sells NAD+ (nicotinamide adenine dinucleotide) · 4 of 4 claims match the trials
- ShedAlso sells Sermorelin · 4 of 6 claims match the trials
- CareBareRXAlso sells NAD+ (nicotinamide adenine dinucleotide) · 2 of 4 claims match the trials
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off VevaRX's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 4 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND injected route AND (skin OR detoxification OR fatigue OR energy) AND randomized controlled trial[pt] — 7 records, none testing injected glutathione alone; ClinicalTrials.gov injected-route glutathione — 3 studies, in lymphoma, acute liver failure and pneumonia. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology. https://clinicaltrials.gov/study/NCT02333071
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.